These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2019 nCoV Review Final.docx (15.32 MB)

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

submitted on 27.01.2020, 00:43 and posted on 27.01.2020, 13:11 by Jared S. Morse, Tyler Lalonde, Shiqing Xu, Wenshe Liu
With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. While little is known about the virus, an examination of the genome sequence shows strong homology with its more well-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations which may hamper efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RdRp and 3CLpro, share a strikingly high (>95%) homology to SARS-CoV. Herein, we suggest 4 potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that can be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad spectrum anti-coronaviral agents for future epidemics.


Studying Reversible Histone Acylations in Nucleosome Contexts

National Institute of General Medical Sciences

Find out more...

Develop General Methods for the Synthesis of Proteins with Posttranslational Lysine Modifications

National Institute of General Medical Sciences

Find out more...

The Preparation of Novel Phage-Displayed Macrocyclic Peptide Libraries for the Identification of Anticancer Agents

Cancer Prevention and Research Institute of Texas

Find out more...


Email Address of Submitting Author


Texas A&M University


United States

ORCID For Submitting Author


Declaration of Conflict of Interest